Deflazacort (Generic) (Deflazacort TABLET) 6 mg/1

Deflazacort is an oral corticosteroid approved by the FDA as an orphan drug for the treatment of Duchenne Muscular Dystrophy (DMD). It was the first corticosteroid specifically approved for DMD, offering an alternative to traditional corticosteroids with a potentially improved side effect profile. This medication belongs to the therapeutic category of neuromuscular agents and immunosuppressants.

Strength

6 mg/1

Pack Size

100 TABLET in 1 BOTTLE (59651-599-01)

Manufacturer / TM Owner

Generic

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Deflazacort is indicated for the treatment of Duchenne Muscular Dystrophy (DMD), a rare, progressive neuromuscular disorder affecting primarily male children. The drug is used to slow the decline in muscle strength and function in DMD patients. Deflazacort works as a corticosteroid that reduces inflammation and modulates immune responses in muscle tissue, helping to preserve muscle function and delay disease progression. The typical patient population includes pediatric and adolescent males diagnosed with genetically confirmed DMD. Treatment is most effective when initiated early in the disease course. Deflazacort offers advantages over conventional corticosteroids due to its unique oxazolidine ring structure, which may result in reduced mineralocorticoid activity and potentially fewer metabolic side effects. The drug helps maintain ambulation, improve motor function, and enhance quality of life in DMD patients.

Side Effects

Common side effects of deflazacort include increased appetite, weight gain, mood changes, sleep disturbances, and gastrointestinal upset. Serious adverse events may include immunosuppression with increased infection risk, hyperglycemia, hypertension, osteoporosis, and adrenal insufficiency with prolonged use. Ophthalmologic complications such as cataracts and glaucoma can occur. Regular monitoring is essential, including periodic assessment of blood glucose, blood pressure, bone density, and ophthalmologic examinations. Patients require monitoring for signs of infection and should receive appropriate vaccinations prior to therapy initiation when possible.

Precautions & Warnings

Deflazacort is contraindicated in patients with systemic fungal infections or known hypersensitivity to the drug. Use with caution in patients with diabetes, hypertension, osteoporosis, or psychiatric disorders. The drug should be avoided or used with extreme caution in pregnancy, particularly during the first trimester, due to potential teratogenic effects. Pediatric patients require careful dose adjustment and growth monitoring. Patients with hepatic or renal impairment may require dose modifications. Live vaccines should be avoided during treatment. Deflazacort should not be abruptly discontinued due to risk of adrenal insufficiency; gradual tapering is necessary.

Avoid Interactions

Deflazacort may interact with medications that induce or inhibit cytochrome P450 enzymes, potentially altering drug levels. Concurrent use with NSAIDs increases gastrointestinal ulceration risk. Deflazacort may reduce the efficacy of live vaccines and certain immunosuppressive agents. Antidiabetic medications may require dose adjustment due to hyperglycemic effects. Patients taking potassium-depleting diuretics require monitoring for hypokalemia. Avoid concurrent use with other corticosteroids unless specifically directed by a physician.

Frequently Asked Questions

Deflazacort is used to treat Duchenne Muscular Dystrophy (DMD), a progressive genetic neuromuscular disorder. It works by reducing inflammation and modulating immune responses in muscle tissue to slow the decline in muscle strength and function. The drug helps maintain mobility and improve quality of life in DMD patients.

Deflazacort is administered orally as tablets. The dosage is typically individualized based on patient weight and clinical response, usually ranging from 0.75 to 1.5 mg/kg/day. It should be taken consistently, preferably with food to minimize gastrointestinal upset, and exactly as prescribed by the physician.

Common side effects include increased appetite, weight gain, mood changes, insomnia, and gastrointestinal disturbances. Long-term use may result in immunosuppression, hyperglycemia, hypertension, and bone density loss. Patients should report persistent or severe side effects to their healthcare provider.

Deflazacort is available as a generic medication from multiple manufacturers. It was originally developed and marketed under the brand name Emflaza by PTC Therapeutics before generic versions became available.

Yes, deflazacort received FDA orphan drug designation for the treatment of Duchenne Muscular Dystrophy. This status recognizes its use in treating a rare disease affecting fewer than 200,000 people in the United States, providing regulatory incentives for development and commercialization.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.